Fetal hemoglobin (HbF) decreases polymerization of
sickle hemoglobin (HbS) and improves outcomes in
sickle cell disease (
SSD). Therefore, a therapeutic goal in
SSD is pharmacologic reactivation of HbF. Silencing of the
gamma-globin (HbF) gene is associated with DNA methylation. The
cytosine analog
5-aza-2'-deoxycytidine (
decitabine) hypomethylates
DNA by inhibiting
DNA methyltransferase. We examined if subcutaneous
decitabine could increase HbF levels and improve
SSD pathophysiology without cytotoxicity. Eight symptomatic
SSD patients resistant or intolerant of standard treatment with
hydroxyurea received
decitabine 0.2 mg/kg subcutaneously 1 to 3 times per week in 2 cycles of 6-week duration. Treatment decreased neutrophils and increased mean HbF (6.5% to 20.4%, P <.0001) and mean total
hemoglobin (76 to 96 g/L [7.6 to 9.6 g/dL], P <.001). Features of vaso-occlusive crisis pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity significantly improved.
gamma-Globin gene promoter methylation decreased, and platelets and the proportion of megakaryocytes and erythroid cells in the marrow increased without a decrease in marrow cellularity, consistent with
a DNA hypomethylating, noncytotoxic mechanism of action. Weekly subcutaneous
decitabine produces cumulative increases in HbF and total
hemoglobin through a noncytotoxic mechanism of action. Chronic dosing and sustained increases in
hemoglobin F and total
hemoglobin levels may be possible. Further studies in
SSD and
thalassemia are indicated.